Thank you, Paul. As he just mentioned, our credit portfolio continues to hold up and performed very well despite a record rise in longer-term reference rates during the quarter. Our SFR loan and multifamily CMBS portfolios remain healthy as well as our life sciences and cGMP investments. While modestly mark-to-market in this environment, our common stock and special situation investments remain a source of opportunistic liquidity, potentially delivering a $0.60 to $0.90 of additional annual CAD once fully monetized. This past week, CBRE published a report confirming the opportunity we outlined last quarter, namely the ability to provide GAAP funding for existing multifamily assets, facing maturities and/or in need of refinancing. In that report, CB outlined a sample set of over $20 billion in near-term maturities meeting this criteria. And given our cadence with -- and relationship with Fannie and Freddie, we are positioned to immediately take advantage of these opportunities in our 13% to 15% all-in yields. To that end, we announced some exciting news this morning that we've been working on as a firm and demonstrates the resources of the NexPoint umbrella. As Brian mentioned, we plan to utilize our talented internal NexPoint sales and distribution team to issue NREF Series B preferred to various retail RIA and institutional advisers. We believe this security provides attractive yields to investors while providing us with accretive capital to deploy into this dislocated market. The near-term opportunities are seemingly endless. Liquidity is scarce as the banking sector is all but shut down. And if there is liquidity, most of it still requires cash in refinancings or assets that have negative leverage profiles. Again, as CBRE indicated in its recent analysis, loans originated from 2018 to 2020 will face refi test funding gap totaling upwards of $20 billion in the multifamily sector. In this environment, we believe we can originate GAAP funding with all in yields in the mid-teens, couple that with structure, guarantees and interest reserves to mitigate our downside risk. Other near-term opportunities include dislocated CMBS, cGMP, life science, first mortgages and B-note purchases was, again, 13% to 15% all-in yields. Collectively, our current pipeline of multifamily and life science investments is north of $300 million. If we're successful in raising and deploying this capital, we do believe we will be the accretion to Invest common stock and earnings is powerful. All told and without any additional leverage, assuming we raise and deploy $300 million, we believe CAD can increase by 20% per year over the next 3 years. To close, we're excited about these opportunities in the coming quarters and pleased with the company's continued stability and the opportunity to go on offense in this environment. As always, I want to thank the team for their hard work. And now, I'd like to turn the call over to the operator for questions.